Abstract
Therapeutic strategies for the prevention of atherosclerosis are essentially based on the correction of major risk factors, such as elevated plasma lipid levels or arterial blood pressure. These interventions have been successful in inducing regression of vascular atherosclerosis, decreasing the incidence of cardiovascular disease, and improving survival in CAD patients. However, with the increasing knowledge of the pathogenesis of atherosclerosis, it appears that the prevention of cardiovascular disease in the future will involve, besides risk factor correction, direct pharmacological control of processes occurring in the arterial wall. These events are largely modulated by factors (growth factors, cytokines, etc.) whose finely tuned balance is modified in areas where the atherosclerotic plaque is developing. Statins, beyond their lipid-lowering effect, interfere with several of these events. It appears that their actions on these processes are linked to the modulation of the mevalonate pathway and could translate into a more significant prevention of cardiovascular disease. Finally, statins due to their ability to improve vascular endothelial function combined with their direct antiatherosclerotic properties, may potentially become part of our therapeutic armamentarium not only for the treatment of hypercholesterolemia but also for the treatment of ischemic coronary syndromes.
| Original language | English |
|---|---|
| Pages (from-to) | 1-12 |
| Number of pages | 12 |
| Journal | Drugs of Today |
| Volume | 32 |
| Issue number | SUPPL A |
| Publication status | Published - 1996 |
Fingerprint
ASJC Scopus subject areas
- Molecular Medicine
- Pharmacology (medical)
- Pharmacology
Cite this
Introduction : Principles of therapeutics of fluvastatin. / Corsini, A.; Fumagalli, R.; Paoletti, R.; Soma, M. R.
In: Drugs of Today, Vol. 32, No. SUPPL A, 1996, p. 1-12.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Introduction
T2 - Principles of therapeutics of fluvastatin
AU - Corsini, A.
AU - Fumagalli, R.
AU - Paoletti, R.
AU - Soma, M. R.
PY - 1996
Y1 - 1996
N2 - Therapeutic strategies for the prevention of atherosclerosis are essentially based on the correction of major risk factors, such as elevated plasma lipid levels or arterial blood pressure. These interventions have been successful in inducing regression of vascular atherosclerosis, decreasing the incidence of cardiovascular disease, and improving survival in CAD patients. However, with the increasing knowledge of the pathogenesis of atherosclerosis, it appears that the prevention of cardiovascular disease in the future will involve, besides risk factor correction, direct pharmacological control of processes occurring in the arterial wall. These events are largely modulated by factors (growth factors, cytokines, etc.) whose finely tuned balance is modified in areas where the atherosclerotic plaque is developing. Statins, beyond their lipid-lowering effect, interfere with several of these events. It appears that their actions on these processes are linked to the modulation of the mevalonate pathway and could translate into a more significant prevention of cardiovascular disease. Finally, statins due to their ability to improve vascular endothelial function combined with their direct antiatherosclerotic properties, may potentially become part of our therapeutic armamentarium not only for the treatment of hypercholesterolemia but also for the treatment of ischemic coronary syndromes.
AB - Therapeutic strategies for the prevention of atherosclerosis are essentially based on the correction of major risk factors, such as elevated plasma lipid levels or arterial blood pressure. These interventions have been successful in inducing regression of vascular atherosclerosis, decreasing the incidence of cardiovascular disease, and improving survival in CAD patients. However, with the increasing knowledge of the pathogenesis of atherosclerosis, it appears that the prevention of cardiovascular disease in the future will involve, besides risk factor correction, direct pharmacological control of processes occurring in the arterial wall. These events are largely modulated by factors (growth factors, cytokines, etc.) whose finely tuned balance is modified in areas where the atherosclerotic plaque is developing. Statins, beyond their lipid-lowering effect, interfere with several of these events. It appears that their actions on these processes are linked to the modulation of the mevalonate pathway and could translate into a more significant prevention of cardiovascular disease. Finally, statins due to their ability to improve vascular endothelial function combined with their direct antiatherosclerotic properties, may potentially become part of our therapeutic armamentarium not only for the treatment of hypercholesterolemia but also for the treatment of ischemic coronary syndromes.
UR - http://www.scopus.com/inward/record.url?scp=0029885927&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029885927&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0029885927
VL - 32
SP - 1
EP - 12
JO - Drugs of Today
JF - Drugs of Today
SN - 0025-7656
IS - SUPPL A
ER -